Concepedia

Author

Jean Powers

Princess Margaret Cancer Centre

Also Known As

J Powers, J. P. Powers, J. POWERS, J. Powers, J.P.S. Powers, Jean Powers

39

Publications

1.8K

Citations

20

H-Index

37

Concepts

All Affiliations

Princess Margaret Cancer CentreJuravinski Cancer CentreQueen's UniversityBC Cancer AgencyOttawa Hospital
JP

About

Jean Powers is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

618

2

Health Sciences

2

2

212

3

Engineering

1

1

15

4

Natural Sciences

1

1

88

5

Biochemistry

1

1

88

Jean Powers

×

22

Publications

1.7K

Citations

18

H-Index

YearCitations

Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

C. Tom Kouroukis, Andrew Belch, Michael Crump,

Journal of Clinical Oncology

2003

280

Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

Christine I. Chen, C. Tom Kouroukis, Darrell White,

Journal of Clinical Oncology

2007

189

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Simon J. Crabb, Demetris Patsios, Eric E. Sauerbrei,

Journal of Clinical Oncology

2008

162

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group

Amit M. Oza, Elizabeth A. Eisenhauer, G. Stanimir,

International Journal of Gynecological Cancer

2004

157

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

Andrew R. Belch, C. Tom Kouroukis, Michael Crump,

Annals of Oncology

2006

156

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

Scott A. Laurie, Isabelle Gauthier, Andrew Arnold,

Journal of Clinical Oncology

2008

120

Effects of single <scp>d</scp>‐amino acid substitutions on disruption of β‐sheet structure and hydrophobicity in cyclic 14‐residue antimicrobial peptide analogs related to gramicidin S

D.L. Lee, Jean Powers, Karin Pflegerl,

Journal of Peptide Research

2004

88

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

Glenwood Goss, Frances A. Shepherd, Scott A. Laurie,

European Journal of Cancer

2008

69

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

A.R. Abdul Razak, Sébastien J. Hotte, Lillian L. Siu,

British Journal of Cancer

2011

63

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

Bernhard J. Eigl, Scott North, Eric Winquist,

Investigational New Drugs

2015

62

Page 1